New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
New Amsterdam Pharma has raised $452.6M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2024.
New Amsterdam Pharma's investors include RA Capital Management, Janus Henderson Investors, Bain Capital Life Sciences, Forbion Capital Partners, Frazier Healthcare Partners.
New Amsterdam Pharma is headquartered in Naarden, The Netherlands.
New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
New Amsterdam Pharma is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"New Amsterdam Pharma — Funding & Investors." VCBacked, December 11, 2024, https://www.vcbacked.co/company/new-amsterdam-pharma. Accessed September 29, 2026.
VCBacked. (2024). New Amsterdam Pharma — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/new-amsterdam-pharma
{{cite web |title=New Amsterdam Pharma — Funding & Investors |url=https://www.vcbacked.co/company/new-amsterdam-pharma |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated